source
- Kairos pushes prostate cancer drug ENV-105 into earlier treatment line after promising mid-phase dataKairos Pharma announced a change to its phase 2 trial of ENV-105, a prostate cancer candidate, moving it to an earlier line of therapy. The modified protocol will enroll patients whose PSA rises a…
- Experts warn FDA against approving Grail’s ineffective multicancer blood testPhysician and cancer‑screening researcher H. Gilbert Welch argues that the FDA should not greenlight Grail’s multicancer blood test, noting the company’s trial of 140,000 participants used a weak s…